Clinical Trials Logo

Inclusion Body Myositis (IBM) clinical trials

View clinical trials related to Inclusion Body Myositis (IBM).

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06450886 Not yet recruiting - Clinical trials for Inclusion Body Myositis (IBM)

Long-term Extension Study of Ulviprubart (ABC008) in Subjects With Inclusion Body Myositis

Start date: September 23, 2024
Phase: Phase 2/Phase 3
Study type: Interventional

ABC008-IBM-202 is an open-label, multicenter study to evaluate the safety and efficacy of long-term administration of ulviprubart (ABC008) in subjects with IBM who have completed either Study ABC008-IBM-101 or Study ABC008-IBM-201. Subjects may be enrolled in this study if they meet study eligibility criteria and: - Have completed the Part 2 (Multiple Ascending Dose [MAD]) End of-Treatment (EOT) Visit in Study ABC008-IBM-101; subjects who continued further on into Part 3 of the study (MAD Extension) prior to enrolling in this study are also eligible; OR - Have completed the Week 80 Follow-up Visit in Study ABC008-IBM-201.